Innovation Paying Off For Hutchison MediTech As It Rakes In 327% Revenue Increase
This article was originally published in PharmAsia News
Executive Summary
Developing new drugs in China for China has never been better for Hutchinson Chi-Med, reporting annual revenues growing by three-fold. The company sees a breakout year in 2014, driven by promising c-Met inhibitor vilotinib licensed to AstraZeneca.